- Molecular NameVerteporfin
- Synonymverteporfin
- Weight718.807
- Drugbank_IDDB00460
- ACS_NO129497-78-5
- Show 2D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)5.01
- pkaN/A
- LogD (pH=7, predicted)2.51
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)N/A
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)N/A
- No.of HBond Donors3
- No.of HBond Acceptors12
- No.of Rotatable Bonds12
- TPSA168.74
- StatusFDA approved
- AdministrationIntravenous
- PharmacologyA benzoporphyrin derivative, is a medication used as a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as the wet form of macular degeneration.
- Absorption_valueN/A
- Absorption (description)N/A
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmMetabolized to a small extent to its diacid metabolite by liver and plasma esterases. NADPH-dependent liver enzyme systems (including the cytochrome P450 isozymes) do not appear to play a role in the metabolism of verteporfin.
- Half lifeFollowing intravenous infusion, verteporfin exhibits a bi-exponential elimination with a terminal elimination half-life of approximately 5-6 hours. Mild hepatic insufficiency increases half-life by approximately 20%.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityOverdose of drug and/or light in the treated eye may result in nonperfusion of normal retinal vessels with the possibility of severe decrease in vision that could be permanent. An overdose of drug will also result in the prolongation of the period during which the patient remains photosensitive to bright light.
- LD50 (rat)N/A
- LD50 (mouse)N/A